Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in Resectable Stage II-IIIB Non-Small Cell Lung Cancer
NCT03456063Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2018
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Apr 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03456063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03456063.